Skip to main navigation
Skip to main content
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Careers
  • Partnerships & Business Development
  • Contact Us
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources
  • Products
  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants
/investor-relations/newsroom

Newsroom

Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
Feb 07, 2023
PDF Version
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
Jan 11, 2023
PDF Version
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
Jan 08, 2023
PDF Version
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
Dec 19, 2022
PDF Version
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 13, 2022
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

-

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-864-6774, or by email at corporateteam@esperion.com.

Leadership Information

Page Tools

Our Company

  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition

Patients

  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources

Products

  • Products

Science

  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants

Careers

  • Careers

Partnerships & Business Development

  • Partnerships & Business Development

Investors & Media

  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Contact Us

  • Contact Us

All trademarks and trade names are the property of their respective owners.

© 2023 Esperion Therapeutics, Inc. All rights reserved. 05/20 US-CRP-2000082

Utility

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines

Search

Share this page